Dissolution: Fundamentals of in vitro release and the biopharmaceutics classification system

Pharmaceutical Product Development: In Vitro-In Vivo Correlation

Volumn , Issue , 2007, Pages 1-28

  Johnson, Kevin C ^a  

^a Molecular Isotope Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 41549164293     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (36)

1. Hidalgo IJ, Raub TJ, Burchardt RT. Characterisation of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989; 96(3):736-749.
2. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeability assay in the description of passive absorption processes. J Med Chem 1998; 41:1070-1110.
3. http://www.intellipharm.com/intellipharmka.htm (accessed May 2005).
4. Fagerholm U, Johansson M, Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm Res 1996; 13(9):1336-1342.
5. Lennernas H, Knutson L, Knutson T, et al. Human effective permeability data for atenolol, metoprolol, propranolol, desipramine and carbamazepine to be used in the proposed biopharmaceutical classification for IR-products. Eur J Pharm Sci 1996; 4(1001):S69.
6. Takamatsu N, Kim O-N, Welage LS, et al. Human jejunal permeability of two polar drugs: cimetidine and ranitidine. Pharm Res 2001; 18(6):742-744.
7. Lennernas H. Human intestinal permeability. J Pharm Sci 1998; 87(4):403-410.
8. Fujimura A, Kumagai Y, Sugimoto K, et al. Circadian influence on effect of propranolol on exercise-induced tachycardia in healthy subjects. Eur J Clin Pharmacol 1990; 38(2):133-137.
9. Lin JH, Yamazaki M. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 2003; 35(4):417-454.
10. Chiou WL, Chung SM, Wu TC, et al. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int J Clin Pharmacol Ther 2001; 39(3):93-101.
11. Johnson KC, Swindell AC. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm Res 1996; 13(12):1795-1798.
12. http://www.intellipharm.com/intellipharmmad.htm (accessed May 2005).
13. Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12(3):413-420.
14. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1887; 19:930-934.
15. Dressman JB, Fleisher D. Mixing-tank model for predicting dissolution rate control of oral absorption. J Pharm Sci 1986; 75(2):109-116.
16. Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm 1989; 51:9-17.
17. Lu ATK, Frisella ME, Johnson KC. Dissolution modeling: factors affecting the dissolution rates of polydisperse powders. Pharm Res 1993; 10(9):1308-1314.
18. Simoes S, Pereira de Almeida L, Figueiredo M. Testing the applicability of classical diffusional models to polydisperse systems. Int J Pharm 1996; 139:169-176.
19. Jinno J, Kamada N, Miyake M, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release 2006; 111:56-64.
20. De Villiers MM. Influence of agglomeration of cohesive particles on the dissolution behaviour of furosemide power. Int J Pharm 1996; 136:175-179.
21. Jounela AJ, Pentikäinen PJ, Sothmann A. Effect of particle size on the bioavailability of digoxin. Eur J Clin Pharmacol 1975; 8:365-370.
22. Higuchi WI, Hiestand EN. Dissolution rates of finely divided drug powders. I. Effect of a distribution of particle sizes in a diffusion-controlled process. J Pharm Sci 1963; 52:67-71.
23. Harriott P. Mass transfer to particles. I. Suspended in agitated tanks. AIChE J 1962; 8:93-101.
24. Bisrat M, Anderberg EK, Barnett MI, et al. Physicochemical aspects of drug release. XV. Investigation of diffusional transport in dissolution of suspended, sparingly soluble drugs. Int J Pharm 1992; 80:191-201.
25. De Almeida LP, Simoes S, Brito P, et al. Modeling dissolution of sparingly soluble multisized powders. J Pharm Sci 1997; 86(6):726-732.
26. Johnson KC. Dissolution and absorption modeling: model expansion to simulate the effects of precipitation, water absorption, longitudinally changing intestinal permeability, and controlled release on drug absorption. Drug Dev Ind Pharm 2003; 29(8):833-842.
27. http://www.fda.gov/cder/OPS/BCS_guidance.htm (accessed July 2005).
28. http://www.fda.gov/cder/guidance/3618fnl.htm (accessed July 2005).
29. Avdeef A, Berger CM, Brownell C. pH-metric solubility 2: correlation between the acid-base titration and the saturation shake-flask solubility-pH methods. Pharm Res 2000; 17(1):85-89.
30. Ran Y, Zhao L, Xu Q, et al. Solubilization of cyclosporin A. AAPS Pharm Sci Tech 2001; 2(1) article 2 (http://www.aapspharmscitech.org/).
31. Hesselink DA, van Gelder T, van Schaik RHN, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76(6):545-556.
32. Chiou WL, Kyle LE. Differential thermal, solubility, and aging studies on various sources of digoxin and digitoxin powder: biopharmaceutical implications. J Pharm Sci 1979; 68(10):1224-1229.
33. Parker RB, Yates CR, Soberman JE, et al. Effects of grapefruit juice on intestinal Pglycoprotein: evaluation using digoxin in humans. Pharmacotherapy 2003; 23(8):979-987.
34. Mosharraf M, Nyström C. Apparent solubility of drugs in partially crystalline systems. Drug Dev Ind Pharm 2003; 29(6):603-622.
35. Yazdanian M, Briggs K, Jankovsky C, et al. The "high solubility" definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. Pharm Res 2004; 21(2):293-299.
36. Swanson DR, Barclay BL, Wong PSL, et al. Nifedipine gastrointestinal therapeutic system. Am J Med 1987; 83(suppl. 6B):3-9.